Naftin Dailymed
Generic: naftifine hydrochloride is used for the treatment of Tinea Pedis Hypersensitivity
Go PRO for all pill images
Rx ONLY
Description
Naftin ® Gel, 1% contains the synthetic, broad-spectrum, antifungal agent naftifine hydrochloride. Naftin ® Gel, 1% is for topical use only.
CHEMICAL NAME
(E)-N-Cinnamyl-N-methyl-1-naphthalenemethylamine hydrochloride. Naftifine hydrochloride has an empirical formula of C 21H 21N•HCl and a molecular weight of 323.86.
Contains
Active Ingredient
Naftifine hydrochloride 1%. Inactive Ingredients
Naftin ® Gel, 1% contains polysorbate 80, carbomer 934P, diisopropanolamine, edetate disodium, alcohol (52%v/v), and purified water.
Clinical Pharmacology
Naftifine Hydrochloride is a synthetic allylamine derivative. The following in vitro data are available but their clinical significance is unknown. Naftifine hydrochloride has been shown to exhibit fungicidal activity in vitro against a broad spectrum of organisms, including Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Epidermophyton floccosum, Microsporum canis, Microsporum audouini, and Microsporum gypseum, and fungistatic activity against Candida species, including Candida albicans. Naftin ® Gel, 1% has only been shown to be clinically effective against the disease entities uled in the INDICATIONS AND USAGE section.
Although the exact mechanism of action against fungi is not known, naftifine hydrochloride appears to interfere with sterol biosynthesis by inhibiting the enzyme squalene 2, 3-epoxidase. This inhibition of enzyme activity results in decreased amounts of sterols, especially ergosterol, and a corresponding accumulation of squalene in the cells.
Pharmacokinetics
In vitro and in vivo bioavailability studies have demonstrated that naftifine penetrates the stratum corneum in sufficient concentration to inhibit the growth of dermatophytes.
Following single topical applications of 3H- labeled naftifine gel 1% to the skin of healthy subjects, up to 4.2% of the applied dose was absorbed. Naftifine and/or its metabolites are excreted via the urine and feces with a half-life of approximately two to three days.
Indications And Usage
Naftin ® Gel, 1% is indicated for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans *Efficacy for this organism in this organ system was studied in fewer than 10 infections. , Epidermophyton floccosum *.
Contraindications
Naftin ® Gel, 1% is contraindicated in individuals who have shown hypersensitivity to any of its components.
Warnings
Naftin ® Gel, 1% is for topical use only and not for ophthalmic use.
Precautions
General
Naftin ® Gel, 1%, is for external use only. If irritation or sensitivity develops with the use of Naftin ® Gel, 1%, treatment should be discontinued and appropriate therapy instituted. Diagnosis of the disease should be confirmed either by direct microscopic examination of a mounting of infected tissue in a solution of potassium hydroxide or by culture on an appropriate medium.
Information for patients
The patient should be told to:
- Avoid the use of occlusive dressings or wrappings unless otherwise directed by the physician.
- Keep Naftin ® Gel, 1% away from the eyes, nose, mouth and other mucous membranes.
Carcinogenesis, mutagenesis, impairment of fertility
In a 2-year dermal carcinogenicity study, naftifine hydrochloride cream was administered to Sprague-Dawley rats at topical doses of 1%, 2% and 3% (10, 20, and 30 mg/kg/day naftifine hydrochloride). No drug-related tumors were noted in this study up to the highest dose evaluated in this study of 30 mg/kg/day [3.6 times the maximum recommended human dose (MRHD) based on mg/m2 comparison].
Naftifine hydrochloride revealed no evidence of mutagenic or clastogenic potential based on the results of two in vitro genotoxicity tests (Ames assay and Chinese hamster ovary cell chromosome aberration assay) and one in vivo genotoxicity test (mouse bone marrow micronucleus assay).
Oral administration of naftifine hydrochloride to rats, throughout mating, gestation, parturition and lactation, demonstrated no effects on growth, fertility or reproduction, at doses up to 100 mg/kg/day (12 times MRHD based on mg/m 2 comparison).
Pregnancy
Teratogenic Effects
Reproduction studies have been performed in rats and rabbits (via oral administration) at doses 150 times or more than the topical human dose and have revealed no evidence of impaired fertility or harm to the fetus due to naftifine. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Nursing mothers
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Naftin ® Gel,1 % is administered to a nursing woman.
Pediatric use
Safety and effectiveness in pediatric patients have not been established.
Adverse Reactions
During clinical trials with Naftin ® Gel, 1%. the incidence of adverse reactions was as follows: burning/stinging (5.0%), itching (1.0%), erythema (0.5%), rash (0.5%), skin tenderness (0.5%).
Dosage And Administration
A sufficient quantity of Naftin ® Gel, 1% should be gently massaged into the affected and surrounding skin areas twice a day, in the morning and evening. The hands should be washed after application. If no clinical improvement is seen after four weeks of treatment with Naftin ® Gel, 1%, the patient should be re-evaluated.
How Supplied
Naftin ® (naftifine hydrochloride) Gel, 1% is supplied in collapsible tubes in the following sizes
- 40g – NDC 54766-770-40
- 60g – NDC 54766-770-60
- 90g – NDC 54766-770-90
STORAGE AND HANDLING SECTION
Note: Store Naftin ® Gel, 1% at room temperature.
Distributed by Sebela Pharmaceuticals Inc.
645 Hembree Parkway, Suite I
Roswell, Georgia 30076
www.sebelapharma.com
Toll Free 1-844-732-3521
© 2018 Sebela Pharmaceuticals Inc. All rights reserved.
Naftin is a registered trademark of Sebela International Limited.
Rev. May 2018
PI 77040001
Principal Display Panel - 40g Tube Carton
NDC 54766-770-40
NAFTIN ® 40g gel
NAFTIFINE HCl 1% GEL
Rx Only
Principal Display Panel - 60g Tube Carton
NDC 54766-770-60
NAFTIN ® 60g gel
NAFTIFINE HCl 1% GEL
Rx Only
Principal Display Panel - 90g Tube Carton
NDC 54766-770-90
NAFTIN ® 90g gel
NAFTIFINE HCl 1% GEL
Rx Only
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
